Möchten Sie immer auf dem neuesten Stand bleiben?

persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus...

New York, March 05, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA...

COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business...

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug...

– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib,...

ITM Announces Phase 3 COMPETE Trial Post-Hoc Subgroup Analyses with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with PNETs at ENETS 2026

— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — —...

Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS(Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNSPreparing protocol resubmission to...

ALX Oncology Q4 and EOY 2025 earnings press release

MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces...